Rosuvastatin 10mg + Fenofibrate 160mg is a combination lipid-lowering therapy designed to manage high cholesterol and triglyceride levels in adults. Rosuvastatin, a potent HMG-CoA reductase inhibitor, reduces LDL cholesterol and total cholesterol, while Fenofibrate, a fibric acid derivative, primarily lowers triglycerides and increases HDL cholesterol. Together, they provide a synergistic effect to improve overall lipid profiles, reducing the risk of cardiovascular events in patients with mixed dyslipidemia. This combination is especially suitable for patients who do not achieve optimal lipid control with monotherapy. Regular monitoring of liver function and lipid levels is recommended during therapy.
